John LaMattina
FDA approvals: 1996 versus 2014
January 12, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs
As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …
Drug prices defy gravity – until patent expiry
June 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina, LaMattina, Pfizer, drug, pharma, pricing, research
How drugs are priced is a hot topic these days, and a new Bloomberg article will cause it to heat-up …
John LaMattina: Pharma’s R&D deals with foundations may hit reputations
June 17, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina
On the surface, it sounds pretty reasonable. Foundations like the Michael J. Fox Foundation and the Cystic Fibrosis Foundation (CFF), …
John LaMattina: Pharma’s reputation continues to suffer – what can be done to fix it?
February 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bad pharma, Goldacre, John LaMattina, industry, transparency
You don’t have too look far to find unflattering articles about the pharmaceutical industry. What was previously the domain of …
John LaMattina: Why was bapineuzamab moved into Phase III trials?
September 24, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AD, John LaMattina, Pfizer, bapineuzamab
The recent news that the Pfizer/J&J Alzheimer’s Disease drug, bapineuzumab (bapi), had failed in critical clinical trials resulted in great …
John LaMattina: FDA tries to disavow role in higher hurdles for new drugs
July 2, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, Pfizer, US, discovery, drug
As evidenced by various blog posts that I have written over the past year (e.g., “Why Doesn’t the FDA Get …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
